SEC Form 4 · accession 0000899243-15-002970
IDEXX LABORATORIES INC /DE · IDXX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael J Williams Ph.D.
Officer — Executive Vice President
Period of report
Aug 10, 2015
Accepted (ET)
Aug 12, 2015 · 5:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874716
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 10, 2015 | S | 3,194 | $77.96 | D | 30,086 | D | |
| Common Stock | Aug 10, 2015 | M | 5,000 | $26.66 | A | 35,086 | D | |
| Common Stock | Aug 10, 2015 | M | 2,482 | $17.19 | A | 37,568 | D | |
| Common StockF2 | Aug 10, 2015 | S | 6,532 | $77.93 | D | 31,036 | D | |
| Common Stock | Aug 10, 2015 | S | 950 | $77.29 | D | 30,086 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (Right to buy)F3 | $17.19 | Aug 10, 2015 | M | 2,482 | D | — | Feb 13, 2016 | Common Stock | 2,482 | 0 | D |
| Non-Qualified Stock Option (Right to buy)F4 | $26.66 | Aug 10, 2015 | M | 5,000 | D | — | Feb 13, 2017 | Common Stock | 5,000 | 6,586 | D |
Explanation of responses
- F1The number of securities reported reflects a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015 (the "Stock Split") and includes 82 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on 6/30/2015.
- F2The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $77.75 and $78.03, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
- F3Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,149 shares on 2/14/2010 and 2/14/2013, 4,150 shares on 2/14/2011 and 2/14/2012 and the remaining 1,241 shares on 2/14/2014, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- F4Grant of option to buy shares of IDEXX Laboratories Inc. common stock that became exercisable as to 3,834 shares on 2/14/2011, 2/14/2012, 2/14/2013 and 2/14/2014 and the remaining 1,959 shares on 2/14/2015, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.